Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, postponed its IPO on Wednesday. The Boston, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GLSS. Piper Jaffray,...read more
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering.
The company's lead candidate uses its proprietary hydrogel technology...read more
9 companies went public in the past week as the IPO market raised $3.5 billion. At 26 deals, November issuance fell one IPO short of last year, unless CVSL manages to price next week. November IPOs raised $7.2 billion and averaged 19% from the offer price,...read more
Neothetics, which is developing an injectable version of an approved asthma drug to reduce belly fat, raised $65 million in an upsized IPO by offering 4.65 million shares (all primary) at $14, the midpoint of the range of $13 to $15. The company originally...read more
Obesity biotech Gelesis does not float shares; $52 million IPO postponed
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, postponed its IPO on Wednesday. The Boston, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GLSS. Piper Jaffray,...read more
The latest weight loss capsule: Gelesis files for a $60 million IPO
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. The company's lead candidate uses its proprietary hydrogel technology...read more
US IPO Weekly Recap: Burgers and bionic eyes gain over 100% as 9 companies go public
9 companies went public in the past week as the IPO market raised $3.5 billion. At 26 deals, November issuance fell one IPO short of last year, unless CVSL manages to price next week. November IPOs raised $7.2 billion and averaged 19% from the offer price,...read more
Neothetics prices upsized IPO at $14 midpoint
Neothetics, which is developing an injectable version of an approved asthma drug to reduce belly fat, raised $65 million in an upsized IPO by offering 4.65 million shares (all primary) at $14, the midpoint of the range of $13 to $15. The company originally...read more